ArticleAmerican journal of translational research2026
Bioinformatics and experimental analysis identify CHN2 and MEF2C as diagnostic biomarkers for tuberculosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe diagnosis, prevention, and treatment of tuberculosis (TB) are crucial for controlling its spread. This study aimed to identify potential pathogenic mechanisms and biomarkers for differentiating active pulmonary TB (PTB) and latent TB (LTB).
methodsMicroarray expression profiles (GSE19439, GSE19442, GSE19444) were retrieved from the GEO database, integrated, and normalized. Differentially expressed genes (DEGs) were obtained by comparing the PTB, LTB, and control groups. Functional enrichment analysis was performed, and potential biomarkers were identified using LASSO regression model, nomogram, and ROC curve analysis. Key candidate genes were further verified in a THP-1-derived macrophage infection system using qRT-PCR, Western blotting and biological assays.
resultsA total of 4044 PTB-associated and 312 LTB-associated DEGs were identified. PTB-associated genes were significantly enriched in viral transcription and NF-κB signaling pathways, whereas LTB-related genes were associated with cellular protective responses and NK cell-mediated cytolysis. Through the 18-gene PTB panel and the 39-gene LTB panel, 13 potential biomarkers were identified, along with 12 genes validated for the second time. Experimental validation confirmed that Chimerin 2 (CHN2) is highly expressed in the PTB model and induces inflammatory responses; However, myocyte enhancer factor 2C (MEF2C) is upregulated in the LTB model and contributes to immune regulation. CHN2 may serve as a primary biomarker for PTB, while LOC653809 and MEF2C may be potential biomarkers for LTB.
conclusionIntegrated bioinformatics and experimental analyses revealed distinct molecular profiles between PTB and LTB. The diagnostic models performed well, and candidate genes, particularly CHN2 and MEF2C, show promise as potential biomarkers for differential TB diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.